BACKGROUND: Diabetes mellitus is associated with substantial morbidity and mortality. With the rise in prevalence of diabetes, there has been an increased need for clinical pharmacy services focused on diabetes management in ambulatory clinics. However, more data IS needed to determine the overall impact that clinical pharmacists have on preventing diabetesrelated inpatient admissions and emergency department (ED) visits for patients with diabetes, especially in an underserved population.
RESULTS: A total of 782 patients met inclusion criteria, 557 in the usual care (control) group and 225 in the clinical pharmacy (intervention) group. PS matching provided a 1:1 matched sample of 220 patients per cohort. When assessing the change in the number of diabetes-related hospitalizations from the pre-index year to the post-index year, patients in the control group had an increase of 8 hospitalizations (8 visits per 220 patients, mean = 0.036, SD = 0.284), while the intervention group had a decrease of 1 hospitalization (-1 visit per 220 patients, mean = -0.005, SD=0.278). Both the t-test (P = 0.06) and GLM model (P = 0.06) indicated that the difference was statistically significant. When assessing the change in the number of diabetes-related ED visits from the pre-index year to the post-index year, we found patients in the control group had an increase of 16 ED visits (16 visits per 220 patients, mean = 0.073, SD = 0.584), while the interven-
R E S E A R C H
• Diabetes mellitus imposes a substantial economic burden on society, and hospitalization costs comprise the largest expenditure. Additionally, elevated hemoglobin A1c is associated with increased diabetes-related complications, including hospitalizations.
• Clinical pharmacist interventions have been associated with mostly positive clinical outcomes on A1c; however, there is limited data on the impact of clinical pharmacy services in preventing diabetes-related hospitalizations and diabetes-related emergency department (ED) visits.
• Indigent populations have barriers to diabetes care that may include, but are not limited to, access to health care, cultural beliefs, and language.
What is already known about this subject
• Patients managed by a clinical pharmacist working under a collaborative drug therapy management protocol had a decrease in the number of hospitalizations during the 1-year follow-up period, while those in the usual care group had an increase in the number of hospitalizations.
What this study adds
tion group had an increase of 4 ED visits (4 visits per 220 patients, mean = -0.018, SD=0.641). Both the t-test (P = 0.18) and GLM model (P = 0.28) indicated that the difference was not statistically significant. A1c levels were reduced in the post-index period for both groups. For the control group, A1c reduction was 1.50 (from 11.17 to 9.67, SD = 2.49). For the intervention group, A1c reduction was 1.90 (from 11.09 to 9.19, SD = 2.44).
Both the t-test (P = 0.04) and GLM model (P = 0.05) indicated that the A1c difference was statistically significant.
CONCLUSIONS: Underserved patients with baseline uncontrolled diabetes who were managed by a clinical pharmacist in the outpatient setting had a higher decrease in A1c compared with usual care. The changes in diabetes-related hospitalizations and diabetes-related ED visits were in the hypothesized direction, but the comparison for ED visits was not statistically significant.
The purpose of this study was to assess the effect of clinical pharmacist involvement in a federally qualified health center (FQHC) on the change in A1c and frequency of diabetesrelated hospitalizations and emergency department (ED) visits.
■■ Methods Study Setting
CommUnityCare is a FQHC with outpatient clinics in Austin, Texas, serving about 66,000 underserved and uninsured patients (http://communitycaretx.org/about/). The majority of patients are enrolled in the Medical Access Program, which is available to Travis County residents who have a household income below the federal poverty guidelines, followed by patients who have federal insurance (i.e., Medicaid, Medicare).
The clinical pharmacy program at CommUnityCare is comprised of pharmacists who have completed at least 1 year of a postdoctoral residency training program. Many of them hold advanced certifications in patient care (i.e., certified diabetes educator) and medication management (i.e., board certified ambulatory care pharmacist). CommUnityCare clinical pharmacists and participating prescribers update the CDTM protocol annually. Some services provided by the individual clinical pharmacists include, but are not limited to, implementing new medications, titrating medications, ordering laboratory panels, counseling on lifestyle modification, providing diabetes education, and managing associated comorbid conditions (i.e., hypertension, dyslipidemia). Under a CDTM protocol, patients referred to the clinical pharmacists for diabetes management are scheduled for a 30-minute visit as often as required to reach the patient's goals (i.e., A1c) and as clinically necessary for patient safety (i.e., to monitor laboratory values).
Data from CommUnityCare covering the period between July 1, 2007, through July 1, 2011 (study period), were used to explore the relationship between clinical pharmacists' interventions and changes in A1c, diabetes-related hospitalizations, and diabetes-related ED visits. This study was a retrospective review via electronic medical records from CommUnityCare, and the patients' data were de-identified. The study was approved by the University of Texas Institutional Review Board and by CommUnityCare.
Patient Selection
Adult patients aged between 18 and 89 years with a diagnosis of type 1 or type 2 diabetes mellitus were identified during the time period of July 1, 2007, through July 1, 2011. Documentation of an A1c value at baseline (defined as within 3 months before or after initial visit with clinical pharmacy or usual care) was required. For enrollment in the study, patients must have had poor glycemic control, defined as an A1c ≥ 9% at baseline, and at least 3 visits with a clinical pharmacist or usual care. Usual care patients were followed by their primary care providers and had no appointments with a clinical pharmacist during the study period. Patients must have been D iabetes mellitus is a major cause of illness in the United States and is a growing public health problem. The diabetes epidemic affects approximately 8.3% of the U.S. population, and its prevalence is increasing, with approximately 79 million Americans at increased risk for diabetes. 1 Besides the risk of complications and the burden of disease on the patient, the cost associated with diabetes is a significant economic burden. Medical expenses for people living with diabetes are more than 2 times higher than for people living without diabetes, and inpatient care continues to be the largest expenditure (43% of total cost). In fact, the American Diabetes Association (ADA) estimates that the total annual cost of diagnosed diabetes rose to $245 billion in 2012 from $174 billion in 2007. 2, 3 Furthermore, the ADA estimated that nearly one-third of patients with diabetes may require 2 or more hospitalizations per year. 4 With the prevalence of diabetes expected to rise, inpatient costs will likely remain a major contributor to diabetes-related costs.
Pharmacy services have expanded from traditional dispensing roles to include comprehensive clinical pharmacy services as part of the health care team. Currently, at least 70% of state boards of pharmacy authorize collaborative drug therapy management (CDTM) protocols between a clinical pharmacist and prescriber in the outpatient setting. 5 In the state of Texas, pharmacists working with a CDTM protocol can initiate, modify, or continue drug therapy for a referred patient. Previous studies have shown the value of clinical pharmacy services in improving health outcomes and reducing economic costs for patients with diabetes. 6 Benefits of CDTM include, but are not limited to, improving patient adherence, decreasing adverse events, avoiding drug interactions, and using the knowledge of the clinical pharmacist to promote enhanced services via direct patient care. [6] [7] [8] Previous studies have shown that patients with diabetes who receive clinical pharmacist interventions demonstrate significantly improved hemoglobin A1c. [7] [8] [9] [10] [11] [12] [13] Furthermore, the data have shown that increased A1c is associated with increased costs per hospitalization. In fact, patients with a mean A1c of at least 10% or greater have significantly higher rates of diabetes-related hospital utilization, compared with patients with a mean A1c of < 7%. 13 However, there is a lack of data for clinical pharmacists' impact on inpatient utilization, especially in underserved populations.
• While both cohorts (usual care vs. clinical pharmacy group) showed a decrease in A1c scores at the 1-year follow-up, there was greater A1c reduction in the clinical pharmacy group. • Clinical pharmacist management of patients with uncontrolled diabetes was associated with improved clinical outcomes in a federally qualified health center. 
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eligible for at least 1 year before and 1 year after their index dates. In addition, a follow-up A1c (at least 1 year post-index) must have been documented in the database.
Patients were excluded if they had a clinical pharmacy visit for any disease state before the study initiation, or if they had a diagnosis of cancer or human immunodeficiency virus, were pregnant, or had diagnosis codes for motor vehicle accidents or chronic pain (i.e., back pain, generalized pain, myalgia).
Study Outcomes
The outcomes of this study were 1-year post-index change in A1c, diabetes-related hospitalizations, and diabetes-related ED visits. Follow-up A1c values at least 1 year post-index were used to calculate the change in A1c from baseline for each patient. The International Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) was used to identify diabetes-related diagnoses ( Table 1 ). The ICD-9-CM codes identified are shortterm complications of diabetes that include hyperglycemia and hypoglycemia, as well as long-term complications of diabetes that include microvascular and macrovascular conditions. A hospitalization or ED visit was considered diabetes-related if 1 of the designated ICD-9-CM codes was documented in the diagnosis fields (up to 5 ICD-9-CM codes could be listed). Diabetes-related ED and hospital visits for 1 year pre-index and 1 year post-index were identified, and the difference in number of events for each patient was calculated.
Statistical Analysis
Clinical pharmacy and usual care groups were propensity score (PS) matched using a 1:1 ratio. Variables used for PS matching were age, gender, pre-index hospitalizations, preindex ED visits, and index A1c values. Sample size estimations were based on change in A1c, which was the primary outcome variable. For a 1-sided t-test of 2 independent means, with an effect size of 0.25, an alpha error P of 0.10, and a power of 95%, we estimated that 275 patients were needed in each group. In addition, to assess the change in A1c values, a general linear model (GLM) was conducted to control for baseline demographics (age, gender, race/ethnicity) and clinical characteristics (pre-index diabetes-related hospitalizations, pre-index diabetes-related ED visits, and index A1c). For the outcomes with count results and a high number of zeros (hospitalizations and ED visits), zero-inflated negative binomial regressions were conducted, again controlling for baseline characteristics. All analyses were conducted with an a priori alpha level of P < 0.10, using SAS version 9.2 (SAS Institute, Inc., Cary, NC).
■■ Results
Patient Characteristics
A total of 782 patients met inclusion criteria (Figure 1) , with 225 intervention patients and 557 control patients. PS matching produced a 1:1 match of 220 patients per group. Demographics characteristics of the 2 cohorts before and after matching are listed in Table 2 . Table 3 provides information on the change in outcomes for both unmatched and matched samples to show similarity for both. T-test results for the matched groups (220 in each group) will be discussed. For the usual care group, the number of 
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hospitalizations for 220 patients was 8 for the pre-index year and 16 for the post-index year, for an increase of 8 hospitalizations (8 per 220, mean = 0.036, standard deviation [SD] = 0.284, or 3.6 hospitalizations per 100 patients). For the clinical pharmacist group, the number of hospitalizations for 220 patients was 6 for the pre-index year and 5 for the post-index year for a decrease of 1 hospitalization (-1 per 220, mean = -0.005, SD = 0.278). The difference in these changes was statistically significant (P = 0.06).
For the usual care group, the number of ED visits for 220 patients was 28 for the pre-index year and 44 for the post-index year, for an increase of 16 visits (16 per 220, mean = 0.073, SD = 0.584, or 7.3 ED visits per 100 patients). For the clinical pharmacist group, the number of ED visits for 220 patients was 30 for the pre-index year and 34 for the post-index year, for an increase of 4 visits (4 per 220, mean = 0.018, SD = 0.641). The difference in these changes was not statistically significant (P = 0.18).
For the matched cohorts, the mean change in A1c was -1.50 (SD = 2.49) for the usual care group, while the mean change for the clinical pharmacist group was -1.90 (SD = 2.44). The difference in A1c reduction was statistically significant (P = 0.04).
In addition to t-tests, GLMs were conducted for these outcomes, controlling for the following covariates: gender, race/ ethnicity, age, number of pre-index diabetes-related ED visits, number of pre-index diabetes-related hospitalizations, and baseline A1c values. The difference in the number of diabetesrelated hospitalizations and the number of ED visits was not normally distributed, as both variables had a high number of zeros and a standard deviation higher than the mean; thus, a negative binomial distribution was assumed for these 2 models. Similar to the t-test results, the difference in the change in hospitalizations and the difference in A1c values were significantly different at the a priori level of significance (P = 0.06 and P = 0.05, respectively), while the change in the number of ED visits was not statistically different (P = 0.26).
■■ Discussion
This study demonstrated that patients with uncontrolled type 1 or type 2 diabetes who had at least 3 visits with a clinical pharmacist had an additional improvement in A1c and diabetes-related hospital visits. In addition, the change in the number of diabetes-related ED visits was different in the expected direction, but this difference was not statistically significant. Previous studies have shown that patients who received pharmacist-managed care demonstrated improved A1c values. [7] [8] [9] [10] [11] [12] [13] Increased A1c is associated with increased costs per hospitalization, and these inpatient costs account for the major expenditure in health spending for patients with diabetes in the United States.
Hospitalizations were considered to be diabetes-related if patients had an ICD-9-CM code listed in any of their diagnosis fields that matched at least 1 of 10 of the study's selected ICD-9-CM codes. Up to 5 ICD-9-CM codes could be listed per event. In contrast, a previous study required the ICD-9-CM code to be listed as the primary or secondary diagnosis to be included for analysis. 8 In our case, all diagnosis field entries were accepted for analysis, since the goal of the study was to identify diabetes-related events, regardless of prioritization of the ICD-9-CM codes. The 10 ICD-9-CM codes identified microvascular complications (i.e., nephropathy, neuropathy, retinopathy) because pharmacologic interventions to normalize glucose can reduce the risk of microvascular complications by 37% for every 1% drop in A1c.
14 A 2010 study used a broader range of ICD-9-CM codes that accounted for macrovascular complications such as ischemic heart disease and stroke, as well as acute complications such as infections. 15 However, a meta-analysis revealed that intensive glucose-lowering therapy modestly reduced major macrovascular events after an average follow-up of 4.4 years in patients with type 2 diabetes. 16 Thus, the length of time to see an effect on macrovascular outcomes precluded the necessity of including ICD-9-CM codes that identified these complications. Because there is large variability in the design of studies that rely on procedural codes for analysis, these are important considerations in designing future strategies to document disease-state complications. Our study identified important findings regarding clinical pharmacy intervention and the effect on inpatient usage in a FQHC.
This study did not look at secondary outcome measures that have been documented in previous studies assessing 
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pharmacist impact on diabetes care. However, clinical pharmacist intervention has been shown to improve patient adherence with the ADA guidelines for preventive care. Significant improvement in health indicators after clinical pharmacy intervention include a decrease in low-density lipoprotein, increase in frequency of microalbumin screening, increase in annual eye and foot examination, and increase in daily aspirin use as appropriate. 17 Furthermore, improvement of quality-of-life measures (i.e., patient satisfaction) have been documented in the literature.
18
Limitations
Since the analysis was retrospective in nature, only associations can be reported, not causality. In addition, retrospective studies do not allow for randomization, so selection bias is possible. Matching was conducted to address this issue, but unmeasured confounders could have played a role in group differences. One common limitation to similar studies comes from small sample sizes. Since less than 300 patients met the inclusion criteria for the intervention group, this limitation reduced the power of the analyses, and a P value less than 0.10 was chosen, based on expected sample size and expected effect size.
The use of ICD-9-CM codes rather than medical records may raise concerns about clinical accuracy. For example, it is possible that the ICD-9-CM code was incorrectly documented, since it cannot be ascertained who input the code into the diagnosis field and whether the code matched the final diagnosis at discharge. Additionally, flaws in the ICD-9-CM system could not be avoided. For example, if a patient was admitted for a diabetes-related foot infection, the provider may not have included the diagnosis because a code does not exist for this exact wording.
Another limitation was the number of hospitals contracted with the database that submitted information relating to hospitalizations and ED visits. Only 2 hospital systems submitted this information; thus, the outcomes were affected by the availability of only local data if a patient was hospitalized or went to the ED at a noncontracted hospital outside of the city.
We assumed that patients only had clinical pharmacist intervention during this time period, but we did not know whether patients received other services that could impact outcomes. For example, if a patient saw a dietician for diabetes nutrition counseling, this interaction could be a variable to improvement of A1c. In addition, the degree/level of clinical pharmacist intervention is not standardized. Clinical pharmacists who work under a CDTM have a variety of roles, depending on the nature and need of the visit. In many instances, the first visit focuses on diabetes education, which includes, but is not limited to, insulin pen administration, glucose monitoring recommendations, nutrition, and preventive services (i.e., immunization recommendations). This study attempted to control for this unknown by requiring that a patient have 3 visits to be included in the study to determine the impact of clinical pharmacist intervention as shown in previous studies. 8, 11 This study was conducted in a FQHC setting; thus, generalizability of the results is limited to underinsured and underserved populations. The majority of the study population was Hispanic (about 70%). Minority populations, especially Hispanic patients, have a higher prevalence of diabetes, worse glycemic control, poor adherence, and more complications than non-Hispanic white patients with diabetes. 11 Previous studies have observed that Hispanics have a lower rate of diabetes-related hospitalizations. 11, 19, 20 Multiple factors contribute to this finding, such as cultural stigma associated with the hospital setting. In this study's demographic, socioeconomic status could prohibit a patient from going to the hospital or ED even when needed. Barriers to health care access also include low English proficiency, low health literacy, lack of personal identification, and misunderstanding of the disease state. 21, 22 ■■ Conclusions For this underserved population of patients with either type 1 or type 2 diabetes, a significant and beneficial relationship was seen in the change in A1c and the change in the number of diabetes-related hospitalizations after 3 visits with a clinical pharmacist when compared with usual care. While the change in ED visits trended in the expected direction, this comparison was not statistically significant. Future research to examine utilization patterns and changes for clinical pharmacy services may be important for expanding CDTM protocols to further improve outcomes for patients with diabetes.
